Phase 1 Completed N=5 Basic Science

PET Imaging and Bariatric Surgery

Obesity, Morbid

Source: ClinicalTrials.gov NCT00801827 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2017

Primary outcomePrimary: Regional DRD2/3 Binding Percent Changes After Bariatric Surgery — -10.14; -9.39; -8.11; -8.76 percentage of binding potential change

Summary

The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2/3) and other studies have shown that obese people have less of these. We propose that low DRD2/3 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.

Outcome Measures

Outcome	Result	p-value
PRIMARY Regional DRD2/3 Binding Percent Changes After Bariatric Surgery	-10.14; -9.39; -8.11; -8.76; -10.2; -8.17	—

Eligibility Criteria

Inclusion Criteria

Ages 18-60 years
BMI equal to or greater than 40, or equal to or greater than 35 if there are 2 or more co-morbidities
Weight less than 350 pounds

Exclusion Criteria

History of substance abuse, including but not limited to alcohol, cocaine, marijuana, heroin, nicotine
History of psychiatric disorders
Use of any antidepressants or psychotropics in the past 12 months
Diabetes Mellitis
Positive pregnancy test
Any condition felt by the PI or co-investigators to interfere with the individual's ability to complete the study
Subjects on medications for the last 3 months, such as sibutramine, which could affect the quality of the study, as determined by the PI
Inability to travel to Nashville, TN four times

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00801827). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.